Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2012 Nov 9:2113–2120. doi: 10.1016/B978-0-12-382219-2.00476-2

Otubains

Benedikt M Kessler 1
Editors: Neil D Rawlings2, Guy Salvesen3
PMCID: PMC7149335

Abstract

The third edition of the Handbook of Proteolytic Enzymes aims to be a comprehensive reference work for the enzymes that cleave proteins and peptides, and contains over 800 chapters. Each chapter is organized into sections describing the name and history, activity and specificity, structural chemistry, preparation, biological aspects, and distinguishing features for a specific peptidase. The subject of Chapter 476 is Otubains.

Keywords:

Otubains, deubiquitylating enzymes, Ubiquitin, Ubiquitin-like proteins, interferon-stimulated genes, Ubiquitin processing enzymes, crystal structure, interferon stimulated genes, ISG15, DUB, OTU, poly-Ubiquitin chains, signal transduction, protein degradation, protein targeting.

Author Biography

Inline graphic Benedikt Kessler graduated from the Swiss Federal Institute of Technology ETH in Zurich, Switzerland in biochemistry in 1992. He received his PhD in immunology at the Ludwig Institute for Cancer Research at the University of Lausanne in 1998. He then joined the laboratory of Hidde L. Ploegh at the Pathology Department at Harvard Medical School in Boston, USA, to study the role of proteolysis in antigen processing and presentation. After three years, he established a research platform in proteomics at Harvard Medical School. Currently he is a University Research Lecturer at the Department of Medicine, University of Oxford, UK. His laboratory is focused on Ubiquitin and protease biology with a specialty in mass spectrometry and proteomics. Expertise in his laboratory is also used to understand disease processes in translational research.

Databanks

MEROPS name: Cezanne-2 peptidase

MEROPS classification: clan CA, family C64, peptidase C64.002

Species distribution: subphylum Vertebrata

Reference sequence from: Homo sapiens (UniProt: Q8TE49)

MEROPS name: A20 peptidase

MEROPS classification: clan CA, family C64, peptidase C64.003

Tertiary structure: Available

Species distribution: subphylum Vertebrata

Reference sequence from: Homo sapiens (UniProt: P21580)

MEROPS name: trabid peptidase

MEROPS classification: clan CA, family C64, peptidase C64.004

Species distribution: subkingdom Metazoa

Reference sequence from: Homo sapiens (UniProt: Q9UGI0)

MEROPS name: VCIP135 deubiquitinating peptidase

MEROPS classification: clan CA, family C64, peptidase C64.006

Species distribution: subphylum Vertebrata

Reference sequence from: Homo sapiens (UniProt: Q96JH7)

MEROPS name: otubain-1

MEROPS classification: clan CA, family C65, peptidase C65.001

Tertiary structure: Available

Species distribution: superkingdom Eukaryota

Reference sequence from: Homo sapiens (UniProt: Q96FW1)

MEROPS name: otubain-2

MEROPS classification: clan CA, family C65, peptidase C65.002

Tertiary structure: Available

Species distribution: subphylum Vertebrata

Reference sequence from: Homo sapiens (UniProt: Q96DC9)

MEROPS name: OTLD1 deubiquitinylating enzyme

MEROPS classification: clan CA, family C85, peptidase C85.001

Species distribution: superkingdom Eukaryota

Reference sequence from: Homo sapiens (UniProt: Q96G74)

MEROPS name: KIAA0459 (Homo sapiens)-like protein

MEROPS classification: clan CA, family C85, peptidase C85.003

Species distribution: superkingdom Eukaryota

Reference sequence from: Homo sapiens

MEROPS name: Otud1 protein

MEROPS classification: clan CA, family C85, peptidase C85.004

Species distribution: phylum Chordata

Reference sequence from: Homo sapiens

MEROPS name: YOD1 peptidase

MEROPS classification: clan CA, family C88, peptidase C88.002

Species distribution: superkingdom Eukaryota

Reference sequence from: Homo sapiens (UniProt: Q5VVQ6)

MEROPS name: OTU1 peptidase (Saccharomyces cerevisiae-type)

MEROPS classification: clan CA, family C88, peptidase C88.001

Tertiary structure: Available

Species distribution: order Saccharomycetales

Reference sequence from: Saccharomyces cerevisiae (UniProt: P43558)

MEROPS name: nairovirus deubiquitinylating peptidase

MEROPS classification: clan CA, family C87, peptidase C87.001

Tertiary structure: Available

Species distribution: known only from Crimean-Congo hemorrhagic fever virus

Reference sequence from: Crimean-Congo hemorrhagic fever virus

Name and History

Ubiquitylation is a reversible reaction, and removal of Ubiquitin (Ub) moieties is mediated by deubiquitylating enzymes (DUBs), which are predominantly enzymes of the cysteine- and metallo-protease families (see Chapters 351, 460–480Chapter 351Chapter 460Chapter 461Chapter 462Chapter 463Chapter 464Chapter 465Chapter 466Chapter 467Chapter 468Chapter 469Chapter 470Chapter 471Chapter 472Chapter 473Chapter 474Chapter 475Chapter 476Chapter 478Chapter 479Chapter 480). DUBs consist of four protease subclasses, the USPs (Chapters 460–462Chapter 460Chapter 461Chapter 462), UCHs (Chapter 463–470Chapter 463Chapter 464Chapter 465Chapter 466Chapter 467Chapter 468Chapter 469Chapter 470), Machado-Josephin domain (MJD) (Chapter 479) and ovarian tumor domain containing protease (OTU) families [1], [2]. The latter is a group of proteins found primarily in viruses, plants, bacteria and eukaryotes. The eukaryotic sequences are originally related to the Ovarian Tumor (OTU) gene in Drosophila, cezanne deubiquitylating peptidase and tumor necrosis factor, alpha-induced protein 3 (MEROPS peptidase family C64) and otubain 1/otubain 2 (MEROPS peptidase family C65) in mammals (Table 477.1 and MEROPS Database).

Table 477.1.

Examples* of Ovarian Tumor Domain (OTU) containing proteases with DUB-like activity

Name(s) Origin UniprotKBa MEROPS Biological function/Substrates References
OTU1 (YOD1, OTUD2, HIN7) human Q5VVQ6 C88 DUB in ERAD [37]
OTUD1 (DUBA-7) human Q5VV17 C85 unknown UniprotKB
OTUB1 (HSPC263) human Q96FW1 C65 DUB stabilizing RNF128, RhoA, ERα, inh. RNF168, TRAF3/6 [38], [39], [40], [41], [44]
OTUB2 human Q96DC9 C65 unknown [10]
OTUD3 human Q5T2D3 unknown UniprotKB
OTUD4/HIN1L human Q01804 C85 unknown UniprotKB
OTUD5 (DUBA) human Q96G74 C85 TRAF3 deubiquitylation [29]
OTUD6A (DUBA2)/6B human Q7L8S5 unknown UniprotKB
OTUD6B (DUBA5) human Q8N6M0 unknown UniprotKB
OTUD7 (Cezanne 2) human Q8TE49 C64 DUB-like activity UniprotKB
VCPIP1 (VCIP135) human Q96JH7 C64 DUB in ER, Golgi [34], [35]
TRABID (ZRANB1) human Q9UGI0 C64 Wnt signaling [32]
A20 (OTUD7C) human P21580 C64 inflammatory signaling Pathways [20], [21]
OTU1 (yOTU1) yeast P43558 C88 interacts with p97/cdc48 [50]
L_CCHFI virus Q6TQR6 C87 de-Ub/ISGylation [47]
OTLD1 plant AT2G27350b C85 histone DUB [51]
*

This list mentions the most commonly characterized proteases containing an OTU domain (in bold). More than ~100 genes containing a conserved OTU domain in eukaryotes, prokaryotes and viruses are predicted to have cysteine protease activity.

a

Accession numbers derived from SwissProt.

b

Accession number derived from UniGene/NCBI.

OTU containing proteins have a sequence encoding a cysteine protease signature that is conserved across plants, viruses to higher eukaryotes. Approximately 100 genes are known to encode OTU domains, and research in recent year has shed light on the biological function of a considerable number of these enzymes establishing their role as Ubiquitin and Ubiquitin-like (Ubl) processing/deubiquitylating enzymes (DUBs). Structural studies of mammalian and viral OTUs reveal a substantial variety in Ubiquitin binding modes, and viral OTUs appear to have acquired the ability to also recognize ISG-15. OTUs play a role in cell biological processes such as ERAD (YOD1), but also immune signaling (Cezanne, DUBA, and OTUB1) and host-pathogen interactions (OTUB1/OTUB2, vOTUs). In this chapter, most recent advances in characterizing the biological functions of members of this DUB enzyme family are discussed.

Activity and Specificity

Sequence comparison bioinformatics revealed an evolutionary conserved domain encoding a cysteine protease motif [3]. This motif was first characterized in a gene that is involved in the development of the Drosophila melanogaster ovary (termed otu gene) where it may regulate the localization and translation of certain RNA transcripts [4], [5]. Using the Drosophila otu gene and its homologs as a starting point, sequence similarities were found between these genes and those encoding viral and plant cysteine proteases.

First functional evidence for general DUB-like activity of OTU domain containing proteins, as demonstrated for OTUB1 (HSPC263), was provided by a chemical proteomics screen using Ubiquitin-based active site probes containing C-terminal elecrophilic groups acting as suicide inhibitors [6]. In subsequent studies, Otubain-1 and Otubain-2 were the first two OTU proteins found to display in vitro DUB activity [7]. Shortly thereafter, Cezanne, another OTU-domain containing protein, was found to interact with poly-Ub in a yeast two-hybrid assay and to contain DUB activity in vitro, suggesting that this is a general OTU feature [8]. Since the discovery of the first ovarian tumor domain (OTU) protease in Drosophila oogenesis and prior to the identification of vOTU, OTU superfamily members could be divided into two subclasses according to their sequence homology, otubains (MEROPS peptidase family C65) and A20-like OTUs including ZRANB1 (MEROPS peptidase family C64). With the addition of the viral OTU subclass, OTU superfamily members count more than 100 eukaryotic, bacterial, and viral proteins have now been identified (for examples, see Table 477.1). Predominantly, OTU proteases have been linked to Ubiquitin (Ub) and Ubiquitin-like protein (Ubl) removal and/or remodeling of Ub/Ubl-conjugated proteins, placing them among the protease superfamilies that facilitate signal transduction cascades and play key roles in protein stability [9].

Structural Chemistry

Sequence comparison of the catalytic regions of OTUs reveals a conserved Cys and His residues (Figure 477.1 ). However, the position of the acidic residue(s) is variable, and the amino acid side chains involved in the hydrogen bonding network responsible for rendering the catalytic thiol more nucleophilic are not always clearly evident from the primary sequence. In attempts to better understand the biological function of proteins belonging to the OTU superfamily, structures of several OTUs and OTU domains have been elucidated. The crystal structure of human OTUB2 confirmed the typical papain-like cysteine protease fold of the OTU domain (Figure 477.2A , left panel) and shows that, unlike other cysteine protease DUBs, the catalytic triad is incomplete and is stabilized by a new method involving a hydrogen bonding network (Figure 477.2A, right panel) [10]. Subsequent X-ray structures of the human A20 OTU domain and OTUB1 indicated that the catalytic site is in an unproductive conformation in the apo enzyme as observed for other DUBs (Figure 477.2B and Johnston et al. [11], Hu et al. [12], and Edelmann et al. [13]). The binding of Ubiquitin leads to a conformational change that rearranges the catalytic site conformation as demonstrated in the crystal structure of yeast ovarian tumor 1 (yOTU1) in complex with mono-Ub [14]. Recently, the crystal structures of viral OTUs in complex with either Ubiquitin or ISG15 provided some insights into the molecular basis for the specificity and cross-reactivity of recognizing Ubiquitin and ISG15. As demonstrated for the structure of Crimean-Congo haemorrhagic fever virus (CCHFV) bound to Ubiquitin, the binding mode resembles the one observed for other mammalian DUBs with Ubiquitin [15], [16], [17]. Interestingly, a comparison with the X-ray structure of CCHFV OTU in complex with ISG15 revealed that ISG15 is bound in an orientation 75° as to the one observed with Ubiquitin [17], thereby exposing different surfaces of the Ub/Ubl substrate to the enzyme [15]. The promiscuity of the CCHFV deubiquitylase towards different Ub/Ubls may represent a common phenomenon for vOTUs as well as other pathogen encoded DUBs, as this is also observed in the severe acute respiratory syndrome (SARS) corona virus encoded DUB PLpro [18] (Chapter 480). The fact that mammalian OTUs appear not to show cross-reactivity towards interferon induced ISG15, but other Ubls such as NEDD8 [13] may demonstrate that vOTUs underwent a co-evolutionary process provoked by host-pathogen interactions. It remains to be seen whether any of the vOTUs may also show reactivity to the other interferon-induced Ubl FAT10, and whether the unique structural properties of vOTUs can be exploited for pharmacological inhibition based on small-molecule strategies as novel antiviral agents.

Figure 477.1.

Figure 477.1

Sequence alignment of several OTU proteases. (A) OTUs are from CCHF virus (vOTU; Sprot accession no. Q6TFZ7), Saccharomyces cerevisiae (yOTU1; PDB accession no. 3BY4_A), PRRSV (NSP2PC; Sprot accession no. C1K780), and Homo sapiens Otubain2 (PDB accession no. 1TFF_A). Secondary structure of vOTU according to the defined secondary structure of proteins (DSSP) algorithm is represented by blue cylinders (helical regions), brown arrows (β-sheet regions), and blue lines (loops). Breaks denote regions where vOTU has residues. Residues involved in vOTU’s catalytic triad are outlined in black boxes. Residues outlined in orange boxes represent those involved in oxyanion hole formation. Colored bars below the sequence alignment indicate vOTU and yOTU1 positions within 4 Å of Ub. Bars under vOTU unique positions are colored light blue with bars under unique yOTU1 positions in red. Equivalent positions in both vOTU and yOTU1 are shown in purple. Positions that form significant salt bridge and H-bond interactions are highlighted by an asterisk; (B) Ub and Ub-like proteins from H. sapiens (PDB accession no. 1UBQ_A), NEDD8 (Sprot accession no. Q15843), and ISG15 (PDB accession no. 1Z2M_A). Colored bars below the sequence alignment indicate Ub positions within 4Å of vOTU and yOTU1. Bars colored light blue and red indicate Ub positions that interact solely with vOTU and yOTU1, respectively. Purple bars indicate Ub residues within 4Å of both vOTU and yOTU1. Amino acids are color coded according to their being non-conserved (white background), similar (lime green background), conserved (green background), or completely conserved (dark-green background, orange lettering) across the four sequences

(with courtesy of Capodagli et al.[16]).

Figure 477.2.

Figure 477.2

A20 and OTUB2 crystal structures reveal a conserved papain-like cysteine protease fold within the ovarian tumor domain but unique catalytic center configurations. (A) Ribbon structure of A20 (left panel) and stereo view of the catalytic center in which the catalytic residues and the relevant hydrogen bonds are highlighted (right panel); (B) Otubain-2 (OTUB2) ribbon structure (left panel and stereo view of the catalytic center in which the catalytic residues and the relevant hydrogen bonds are highlighted (right panel)

(with courtesy of Komander & Barford [52]).

Preparation

Mammalian and viral OTU genes have been cloned and expressed as recombinant enzymes in bacterial expression systems. Some of these constructs are available commercially (ENZO Life Sciences, Life Sensors, Boston Biochem), but the majority of them are only available through academic research groups.

Biological Aspects

A20 and Inflammation

A20 was first characterized in human umbilical vein endothelial cells predominantly induced by the cytokines TNFα, IL-1β, and LPS [19]. A20 is also known as tumor necrosis factor-a-induced protein 3 (TNFAIP3). Analysis of the A20 domain revealed seven repeats of an A20-type zinc finger (ZnF-A20) in one single polypeptide chain, which exhibits E3 ligase activity, modulating the ubiquitylation status of key adaptors in the NF-κB signaling cascade [20], [21]. The OTU domain that contains DUB protease activity is located at the N-terminus of A20. Overexpression of A20 inhibits TNF-mediated cell death and down-regulates NF-κB signaling. Upon treatment with TNF, A20 expression was found to increase in variety of cells [20]. Mice deficient in A20 were prone to inflammation, and persistent activation of NF-κB by Toll-like and TNF receptors was observed in these mice [22]. Thus, A20 is critical for limiting inflammation by terminating TNF induced NF-κB responses in vivo. The constitutive expression of A20 in different cell types prevents TNFα-induced cell apoptosis. Furthermore, it has been reported that a loss of A20 expression increased the lethality of TNF-α and lipopolysaccharides due to activation of NF-κB [23]. The importance of A20 as a modulator of immunopathology is underpinned by the genetic association between several mutations in the human A20 locus and immunopathologies such as Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and type 1 diabetes [24], [25]. More recently, A20 was discovered to interact with the E3 ligase RNF11 and the E2 enzymes UBC13 Ubc5c, the latter of which antagonizes the activity of the E3 ligases TRAF6, TRAF2 and clAP1, thereby providing a direct mechanism of action of A20 terminating NF-κB activation [26], [27]. Taken together, A20 represents an OTU with a central role in regulating inflammation, and mutations are associated with many autoimmune pathologies as well as B-cell malignancies, such as Hodgkin lymphomas [28].

Cezanne, TRABID, DUBA – Regulation of Immune Signaling Pathways

A number of other DUBs, in particular OTUs, have been found to also play a role in immune signaling pathways. Interferon type I (IFN-I) responses are triggered by pattern-recognition receptors (PRRs), and DUBA (OTUD5) was shown to negatively regulate this immune signaling pathway [29]. DUBA directly binds tumor necrosis factor receptor-associate factor 3 (TRAF3) and cleaves its K63-linked polyubiquitin chains, and its expression is suppressed during IL-1R1 stimulation [30].

Two additional A20-like proteins have been identified and shown to play a role in immune signaling pathways. Cellular zinc finger anti-NF-κ B (Cezanne) and TRAF binding domain (TRABID) appear to interact with TRAF6 [31]. Cezanne has a negative effect on NF-κB activation, whereas TRABID activates Wnt-induced transcription [32]. These OTUs may also have other as yet undiscovered biological functions, as TRABID appears to have a preference of cleaving K29-linked over K63-linked polyubiquitin chains [33].

Roles of YOD1 and VCIP135 in ER Associated Protein Trafficking

A different subset of OTUs is involved in endoplasmic reticulum and Golgi associated biology. Initially, the AAA-ATPase p97/p47 complex was discovered to be required for heterotypic fusion of transport vesicles and assembly of mitotic Golgi fragments, and VCIP135 (VCIPI1) identified as an essential associated factor [34], [35]. More recent studies on p97ATPase-mediated membrane fusion revealed that VCIP135 deubiquitylating activity is required for the p97/p47- but not the p97/p37-dependent pathway [36]. YOD1 (OTU1/OTUD2), another OTU family member, is directly implicated in the dislocation of misfolded proteins from the ER to the cytosol [37].

Pleiotropic Role of OTUB1

OTUB1 is abundantly expressed in most tissues [7] and was originally described as part of a complex including the E3 Ubiquitin ligase GRAIL (gene related to activation in lymphocytes) and USP8, and involved in regulating T-cell anergy [38]. However, OTUB1’s ubiquituous expression profile predicts that it has additional biological roles not restricted to the lymphocytic lineage. Indeed, levels of oestrogen receptor α, TRAF3/6 and the small GTPase RhoA were suggested to be modulated by OTUB1 through direct deubiquitylation or indirect effects [39], [40], [41]. In addition, OTUB1 was found to regulate p53 stability [42] and bind UBC13 [43]. The latter negatively affects the Ubiquitin ligase RNF168 resulting in an inhibition of the DNA damage response [44]. The interaction with UBC13 and stabilization of p53 appear to be independent of its deubiquitylation activity (non-canonical effect), which may represent a different way that OTUs and perhaps other DUBs can function. The fact that OTUB1 binds UBC13 may have affects on other UBC13 dependent E3 ligases, which could explain its pleiotropic affect on many different (indirect) substrates. OTUB1 has DUB-like activity with an almost exclusive preference for K48-linked poly-Ubiquitin [7], [13], suggesting that it may have DUB enzyme activity-dependent and independent functions.

Viral OTUs

The Ubiquitin-like protein ISG15 (Interferon stimulated gene 15) resembles a di-Ubiquitin moiety and mediates an antiviral response to certain viruses. Nairoviruses and Arteriviruses, two unrelated groups of RNA viruses, encode for ovarian tumor domain-containing sequences[45], [46]. These viral OTUs appear to be expressed and to exert DUB-like activity as well as the ability to recognize and cleave ISG15, thereby inhibiting Ubiquitin and ISG15-dependent antiviral pathways [47]. For instance, for the porcine reproductive and respiratory syndrome (PRRS) virus, it was shown that the N-terminal part of the non-structural protein 2 (nsp2) inhibits NF-κB activation [48]. In addition, the Artevirus and Nairovirus OTUs target RIG-1-like receptors, a family of cytosolic RNA helicases that with Toll-like receptors (TLRs) belong to the family of pattern recognition receptors. In the case of Artevirus and Nairovirus derived OTUs, RIG-1 is deubiquitylated, thereby interfering with the signal induced by recognizing foreign RNA [49]. VOTUs are unique in that they are the only OTUs to have shown both deubiquitylating and deISGylating activity. In comparison, Otubain1/2 prefer K48-, K63-linked poly-Ub or NEDD8 (neural precursor cell expressed, developmentally downregulated 8) as substrates [7], [13]. A20 and A20-like Cezanne OTU proteases selectively cleave K63-linked poly-Ub target and DUBA also shows preference for K63-linked poly-Ub [8], [20], [29]. This implies a considerable variation of the OTU domain to accommodate extended functionalities, in particular in viral genes to exploit the modulation of host-pathogen interactions.

Further Reading

The reader is directed to Reyes-Turcu et al. [1], Nijman et al. [2], Sowa et al. [43], and Frias-Staheli et al. [47].

References

  • 1.Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 2009;78:363–397. doi: 10.1146/annurev.biochem.78.082307.091526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123(5):773–786. doi: 10.1016/j.cell.2005.11.007. [DOI] [PubMed] [Google Scholar]
  • 3.Makarova K.S., Aravind L., Koonin E.V. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci. 2000;25(2):50–52. doi: 10.1016/s0968-0004(99)01530-3. [DOI] [PubMed] [Google Scholar]
  • 4.Goodrich J.S., Clouse K.N., Schupbach T. Hrb27C, Sqd and Otu cooperatively regulate gurken RNA localization and mediate nurse cell chromosome dispersion in Drosophila oogenesis. Development. 2004;131(9):1949–1958. doi: 10.1242/dev.01078. [DOI] [PubMed] [Google Scholar]
  • 5.Steinhauer W.R., Walsh R.C., Kalfayan L.J. Sequence and structure of the Drosophila melanogaster ovarian tumor gene and generation of an antibody specific for the ovarian tumor protein. Mol. Cell Biol. 1989;9(12):5726–5732. doi: 10.1128/mcb.9.12.5726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Borodovsky A., Ovaa H., Kolli N., Gan-Erdene T., Wilkinson K.D., Ploegh H.L., Kessler B.M. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 2002;9(10):1149–1159. doi: 10.1016/s1074-5521(02)00248-x. [DOI] [PubMed] [Google Scholar]
  • 7.Balakirev M.Y., Tcherniuk S.O., Jaquinod M., Chroboczek J. Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 2003;4(5):517–522. doi: 10.1038/sj.embor.embor824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Evans P.C., Smith T.S., Lai M.J., Williams M.G., Burke D.F., Heyninck K., Kreike M.M., Beyaert R., Blundell T.L., Kilshaw P.J. A novel type of deubiquitinating enzyme. J. Biol. Chem. 2003;278(25):23180–23186. doi: 10.1074/jbc.M301863200. [DOI] [PubMed] [Google Scholar]
  • 9.Katz E.J., Isasa M., Crosas B. A new map to understand deubiquitination. Biochem. Soc. Trans. 2010;38(Pt 1):21–28. doi: 10.1042/BST0380021. [DOI] [PubMed] [Google Scholar]
  • 10.Nanao M.H., Tcherniuk S.O., Chroboczek J., Dideberg O., Dessen A., Balakirev M.Y. Crystal structure of human otubain 2. EMBO Rep. 2004;5(8):783–788. doi: 10.1038/sj.embor.7400201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Johnston S.C., Larsen C.N., Cook W.J., Wilkinson K.D., Hill C.P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 Å resolution. EMBO J. 1997;16(13):3787–3796. doi: 10.1093/emboj/16.13.3787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hu M., Li P., Song L., Jeffrey P.D., Chenova T.A., Wilkinson K.D., Cohen R.E., Shi Y. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 2005;24(21):3747–3756. doi: 10.1038/sj.emboj.7600832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Edelmann M.J., Iphofer A., Akutsu M., Altun M., di Gleria K., Kramer H.B., Fiebiger E., Dhe-Paganon S., Kessler B.M. Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem. J. 2009;418(2):379–390. doi: 10.1042/BJ20081318. [DOI] [PubMed] [Google Scholar]
  • 14.Messick T.E., Russell N.S., Iwata A.J., Sarachan K.L., Shiekhattar R., Shanks J.R., Reyes-Turcu F.E., Wilkinson K.D., Marmorstein R. Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein. J. Biol. Chem. 2008;283(16):11038–11049. doi: 10.1074/jbc.M704398200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Akutsu M., Ye Y., Virdee S., Chin J.W., Komander D. Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains. Proc. Natl. Acad. Sci. USA. 2011;108(6):2228–2233. doi: 10.1073/pnas.1015287108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Capodagli G.C., McKercher M.A., Baker E.A., Masters E.M., Brunzelle J.S., Pegan S.D. Structural analysis of a viral ovarian tumor domain protease from the Crimean-Congo hemorrhagic fever virus in complex with covalently bonded ubiquitin. J. Virol. 2011;85(7):3621–3630. doi: 10.1128/JVI.02496-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.James T.W., Frias-Staheli N., Bacik J.P., Levingston Macleod J.M., Khajehpour M., Garcia-Sastre A., Mark B.L. Structural basis for the removal of ubiquitin and interferon-stimulated gene 15 by a viral ovarian tumor domain-containing protease. Proc. Natl. Acad. Sci. USA. 2011;108(6):2222–2227. doi: 10.1073/pnas.1013388108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch. Biochem. Biophys. 2007;466(1):8–14. doi: 10.1016/j.abb.2007.07.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Evans P.C., Kilshaw P.J. Interleukin-13 protects endothelial cells from apoptosis and activation: association with the protective genes A20 and A1. Transplantation. 2000;70(6):928–934. doi: 10.1097/00007890-200009270-00010. [DOI] [PubMed] [Google Scholar]
  • 20.Evans P.C., Ovaa H., Hamon M., Kilshaw P.J., Hamm S., Bauer S., Ploegh H.L., Smith T.S. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 2004;378(Pt 3):727–734. doi: 10.1042/BJ20031377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wertz I.E., O’Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature. 2004;430(7000):694–699. doi: 10.1038/nature02794. [DOI] [PubMed] [Google Scholar]
  • 22.Boone D.L., Turer E.E., Lee E.G., Ahmad R.C., Wheeler M.T., Tsui C., Hurley P., Chien M., Chai S., Hitotsumatsu O., McNally E., Pickart C., Ma A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 2004;5(10):1052–1060. doi: 10.1038/ni1110. [DOI] [PubMed] [Google Scholar]
  • 23.Hitotsumatsu O., Ahmad R.C., Tavares R., Wang M., Philpott D., Turer E.E., Lee B.L., Shiffin N., Advincula R., Malynn B.A., Werts C., Ma A. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 2008;28(3):381–390. doi: 10.1016/j.immuni.2008.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30(8):383–391. doi: 10.1016/j.it.2009.05.007. [DOI] [PubMed] [Google Scholar]
  • 25.Martin F., Dixit V.M. A20 edits ubiquitin and autoimmune paradigms. Nat. Genet. 2011;43(9):822–823. doi: 10.1038/ng.916. [DOI] [PubMed] [Google Scholar]
  • 26.Shembade N., Parvatiyar K., Harhaj N.S., Harhaj E.W. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling. EMBO J. 2009;28(5):513–522. doi: 10.1038/emboj.2008.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shembade N., Ma A., Harhaj E.W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science. 2010;327(5969):1135–1139. doi: 10.1126/science.1182364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Malynn B.A., Ma A. A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. J. Exp. Med. 2009;206(5):977–980. doi: 10.1084/jem.20090765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kayagaki N., Phung Q., Chan S., Chaudhari R., Quan C., O’Rourke K.M., Eby M., Pietras E., Cheng G., Bazan J.F., Zhang Z., Arnott D., Dixit V.M. DUBA: a deubiquitinase that regulates type I interferon production. Science. 2007;318(5856):1628–1632. doi: 10.1126/science.1145918. [DOI] [PubMed] [Google Scholar]
  • 30.Gonzalez-Navajas J.M., Law J., Nguyen K.P., Bhargava M., Corr M.P., Varki N., Eckmann L., Hoffman H.M., Lee J., Raz E. Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J. Exp. Med. 2010;207(13):2799–2807. doi: 10.1084/jem.20101326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Evans P.C., Taylor E.R., Coadwell J., Heyninck K., Beyaert R., Kilshaw P.J. Isolation and characterization of two novel A20-like proteins. Biochem. J. 2001;357(Pt 3):617–623. doi: 10.1042/0264-6021:3570617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tran H., Hamada F., Schwarz-Romond T., Bienz M. Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains. Genes Dev. 2008;22(4):528–542. doi: 10.1101/gad.463208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Virdee S., Ye Y., Nguyen D.P., Komander D., Chin J.W. Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. Nat. Chem. Biol. 2010;6(10):750–757. doi: 10.1038/nchembio.426. [DOI] [PubMed] [Google Scholar]
  • 34.Uchiyama K., Jokitalo E., Kano F., Murata M., Zhang X., Canas B., Newman R., Rabouille C., Pappin D., Freemont P., Kondo H. VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo. J. Cell Biol. 2002;159(5):855–866. doi: 10.1083/jcb.200208112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wang Y., Satoh A., Warren G., Meyer H.H. VCIP135 acts as a deubiquitinating enzyme during p97-p47-mediated reassembly of mitotic Golgi fragments. J. Cell Biol. 2004;164(7):973–978. doi: 10.1083/jcb.200401010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Totsukawa G., Kaneko Y., Uchiyama K., Toh H., Tamura K., Kondo H. VCIP135 deubiquitinase and its binding protein, WAC, in p97ATPase-mediated membrane fusion. EMBO J. 2011;30(17):3581–3593. doi: 10.1038/emboj.2011.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ernst R., Mueller B., Ploegh H.L., Schlieker C. The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER. Mol. Cell. 2009;36(1):28–38. doi: 10.1016/j.molcel.2009.09.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Soares L., Seroogy C., Skrenta H., Anandasabapathy N., Lovelace P., Chung C.D., Engleman E., Fathman C.G. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat. Immunol. 2004;5(1):45–54. doi: 10.1038/ni1017. [DOI] [PubMed] [Google Scholar]
  • 39.Stanisic V., Malovannaya A., Qin J., Lonard D.M., O’Malley B.W. OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J. Biol. Chem. 2009;284(24):16135–16145. doi: 10.1074/jbc.M109.007484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Edelmann M.J., Kramer H.B., Altun M., Kessler B.M. Post-translational modification of the deubiquitinating enzyme otubain 1 modulates active RhoA levels and susceptibility to Yersinia invasion. FEBS J. 2010;277(11):2515–2530. doi: 10.1111/j.1742-4658.2010.07665.x. [DOI] [PubMed] [Google Scholar]
  • 41.Li S., Zheng H., Mao A.P., Zhong B., Li Y., Liu Y., Gao Y., Ran Y., Tien P., Shu H.B. Regulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. J. Biol. Chem. 2010;285(7):4291–4297. doi: 10.1074/jbc.M109.074971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Sun X.X., Challagundla K.B., Dai M.S. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 2011;31:576–592. doi: 10.1038/emboj.2011.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sowa M.E., Bennett E.J., Gygi S.P., Harper J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138(2):389–403. doi: 10.1016/j.cell.2009.04.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nakada S., Tai I., Panier S., Al-Hakim A., Iemura S., Juang Y.C., O’Donnell L., Kumakubo A., Munro M., Sicheri F., Gingras A.C., Natsume T., Suda T., Durocher D. Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature. 2010;466(7309):941–946. doi: 10.1038/nature09297. [DOI] [PubMed] [Google Scholar]
  • 45.Honig J.E., Osborne J.C., Nichol S.T. Crimean-Congo hemorrhagic fever virus genome L RNA segment and encoded protein. Virology. 2004;321(1):29–35. doi: 10.1016/j.virol.2003.09.042. [DOI] [PubMed] [Google Scholar]
  • 46.Kinsella E., Martin S.G., Grolla A., Czub M., Feldmann H., Flick R. Sequence determination of the Crimean-Congo hemorrhagic fever virus L segment. Virology. 2004;321(1):23–28. doi: 10.1016/j.virol.2003.09.046. [DOI] [PubMed] [Google Scholar]
  • 47.Frias-Staheli N., Giannakopoulos N.V., Kikkert M., Taylor S.L., Bridgen A., Paragas J., Richt J.A., Rowland R.R., Schmaljohn C.S., Lenschow D.J., Snijder E.J., García-Sastre A., Virgin H.W., IVth Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe. 2007;2(6):404–416. doi: 10.1016/j.chom.2007.09.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Sun Z., Chen Z., Lawson S.R., Fang Y. The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism functions. J. Virol. 2010;84(15):7832–7846. doi: 10.1128/JVI.00217-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.van Kasteren P.B., Beugeling C., Ninaber D.K., Frias-Staheli N., van Boheemen S., Garcia-Sastre A., Snijder E.J., Kikkert M. Arterivirus and nairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling. J. Virol. 2012;86(2):773–785. doi: 10.1128/JVI.06277-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rumpf S., Jentsch S. Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone. Mol. Cell. 2006;21(2):261–269. doi: 10.1016/j.molcel.2005.12.014. [DOI] [PubMed] [Google Scholar]
  • 51.Krichevsky A., Zaltsman A., Lacroix B., Citovsky V. Involvement of KDM1C histone demethylase-OTLD1 otubain-like histone deubiquitinase complexes in plant gene repression. Proc. Natl Acad. Sci. USA. 2011;108(27):11157–11162. doi: 10.1073/pnas.1014030108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Komander D., Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem. J. 2008;409(1):77–85. doi: 10.1042/BJ20071399. [DOI] [PubMed] [Google Scholar]

Articles from Handbook of Proteolytic Enzymes are provided here courtesy of Elsevier

RESOURCES